Tinengotinib not checked
TransThera Sciences (Nanjing), Inc. · TT-00420
FollowEvery change as it happens, and a Monday email
Trials
6 active
11 in total · 1 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.”In the company’s words, NCT05948475 on ClinicalTrials.gov
- Tested for
- Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma, Cholangiocarcinoma Metastatic, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer (CRPC)
- Main trialPhase 3
- “This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma”In the company’s words, NCT05948475 on ClinicalTrials.gov
- Other names
- TT-00420 · preferred combination · selected combination
Other drugs for Cholangiocarcinoma
- FutibatinibTaiho · Phase 2/3
- CTX-009Compass Therapeutics · Phase 2/3
- NanvuranlatJ-Pharma Co., Ltd. · Phase 3
- IvosidenibServier Bio-Innovation LLC · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- D07001-softgelInnoPharmax Inc. · Phase 3
Coming up5
- DecPhase 3 trial completes · ClinicalTrials.gov
- 10 May 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2026 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | |
| Phase 3Not yet recruiting | 31 Dec 2029 | Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | |
| Phase 2Active, not recruiting | 27 Jul 2025 | Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor | |
| Phase 2Recruiting | 10 May 2027 | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | |
| Phase 2Recruiting | 30 Jun 2027 | Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment | |
| Phase 2Recruiting | 31 Dec 2028 | Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) | |
| Phase 2Completed | 28 Feb 2024 | Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma | |
| Phase 1/2Completed | 20 Feb 2024 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | |
| Phase 1/2Completed | 31 Aug 2024 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 7 Mar 2021 | Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers | |
| Phase 1Completed | 31 Jan 2023 | Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026